ES2095749T3 - Compuestos de alquilamino etinil alanina amino diol imidazolil/bencimidazolil-terminados utiles para el tratamiento de la hipertension. - Google Patents

Compuestos de alquilamino etinil alanina amino diol imidazolil/bencimidazolil-terminados utiles para el tratamiento de la hipertension.

Info

Publication number
ES2095749T3
ES2095749T3 ES94908098T ES94908098T ES2095749T3 ES 2095749 T3 ES2095749 T3 ES 2095749T3 ES 94908098 T ES94908098 T ES 94908098T ES 94908098 T ES94908098 T ES 94908098T ES 2095749 T3 ES2095749 T3 ES 2095749T3
Authority
ES
Spain
Prior art keywords
hypertension
treatment
bencimidazolyl
imidazolil
ethinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94908098T
Other languages
English (en)
Inventor
Gunnar J Hanson
Robert E Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2095749T3 publication Critical patent/ES2095749T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS COMPUESTOS CARACTERIZADOS GENERALMENTE COMO DERIVADOS DEL AMINO DIOL DE ALQUILAMINO-ETINIL-ALANINA TERMINADOS EN IMIDAZOLILO/BENZIMIDAZOLILO SON UTILES COMO INHIBIDORES DE LA RENINA PARA EL TRATAMIENTO DE LA HIPERTENSION. COMPUESTOS DE PARTICULAR INTERES SON AQUELLOS DE LA FORMULA (I), EN LA QUE A SE SELECCIONA ENTRE CO Y SO2; X SE SELECCIONA ENTRE UN ATOMO DE OXIGENO Y METILENO; B SE SELECCIONA ENTRE GRUPOS DE IMIDAZOLILO Y BENCIIMIDAZOLILO; R1 SE SELECCIONA ENTRE HIBRIDO, METILO, ETILO, ISOPROPILO Y N-PROPILO; R2 Y R3 FENILMETILO; CADA R3 Y R5 ES HIBRIDO; R4 SE SELECCIONA ENTRE ( ) EN DONDE V SE SELECCIONA ENTRE HIBRIDO Y METILO; R6 ES CICLOHEXILMETILO; R7 SE SELECCIONA ENTRE ISOBUTILO, CICLOPROPILO Y CICLOPROPILMETILO; Q ES UN NUMERO SELECCIONADO ENTRE 0 Y 3; Y N ES UN NUMERO SELECCIONADO ENTRE 0 Y 3; TAMBIEN SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS COMPUESTOS.
ES94908098T 1992-08-14 1993-08-13 Compuestos de alquilamino etinil alanina amino diol imidazolil/bencimidazolil-terminados utiles para el tratamiento de la hipertension. Expired - Lifetime ES2095749T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/930,076 US5373017A (en) 1992-08-14 1992-08-14 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Publications (1)

Publication Number Publication Date
ES2095749T3 true ES2095749T3 (es) 1997-02-16

Family

ID=25458896

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94908098T Expired - Lifetime ES2095749T3 (es) 1992-08-14 1993-08-13 Compuestos de alquilamino etinil alanina amino diol imidazolil/bencimidazolil-terminados utiles para el tratamiento de la hipertension.

Country Status (11)

Country Link
US (3) US5373017A (es)
EP (1) EP0655059B1 (es)
JP (1) JPH08500118A (es)
AT (1) ATE146460T1 (es)
AU (1) AU669005B2 (es)
CA (1) CA2136838A1 (es)
DE (1) DE69306794T2 (es)
DK (1) DK0655059T3 (es)
ES (1) ES2095749T3 (es)
GR (1) GR3022103T3 (es)
WO (1) WO1994004508A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115867A1 (en) * 1992-08-14 2002-08-22 Hanson Gunnar J. Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5373017A (en) * 1992-08-14 1994-12-13 G. D. Searle & Co. Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5508466A (en) * 1994-04-13 1996-04-16 G.D. Searle & Co. Synthesis of N-protected-α-substituted-glycine racemic esters by zinc-mediated addition of organic halide to glycine cation equivalent
US7355068B2 (en) * 2006-01-04 2008-04-08 Eastman Chemical Company Oxidation system with internal secondary reactor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769271A (en) * 1971-04-15 1973-10-30 Lilly Co Eli N-protected amino acids and peptides
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
EP0181110A3 (en) * 1984-10-22 1988-05-11 Kissei Pharmaceutical Co. Ltd. Histidine derivatives as renin inhibitors
SU1676454A3 (ru) * 1984-11-30 1991-09-07 Санкио Компани Лимитед (Фирма) Способ получени пептидов или их фармацевтически приемлемых солей
DK34086A (da) * 1985-01-23 1986-07-24 Abbott Lab Peptidylaminodioler
JPS61236770A (ja) * 1985-04-15 1986-10-22 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
JPS6256458A (ja) * 1985-09-04 1987-03-12 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
JPS63503380A (ja) * 1986-01-16 1988-12-08 アボット・ラボラトリーズ ペプチド類似体
IL81234A (en) * 1986-01-16 1992-09-06 Abbott Lab Peptidylaminodiols,process for their preparation and pharmaceutical compositions comprising them
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
US4921855A (en) * 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
US5036051A (en) * 1987-10-06 1991-07-30 Abbott Laboratories Glaucoma treatment
US5036053A (en) * 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
US4902706A (en) * 1988-07-01 1990-02-20 G. D. Searle & Co. Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents
IE902446A1 (en) * 1989-07-26 1991-02-13 Abbott Lab Peptidyl aminodiol renin inhibitors
US5175181A (en) * 1989-12-04 1992-12-29 G. D. Searle & Co. Imidazolyl/imidazolylalkyl-N-terminal amino hydroxy
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
EP0539976A1 (en) * 1991-10-29 1993-05-05 G.D. Searle & Co. Ethynyl-alanine-amino-diol compounds for treatment of hypertension
US5373017A (en) * 1992-08-14 1994-12-13 G. D. Searle & Co. Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Also Published As

Publication number Publication date
AU669005B2 (en) 1996-05-23
ATE146460T1 (de) 1997-01-15
GR3022103T3 (en) 1997-03-31
US20030130329A1 (en) 2003-07-10
EP0655059A1 (en) 1995-05-31
DK0655059T3 (da) 1997-01-06
DE69306794T2 (de) 1997-05-07
US5373017A (en) 1994-12-13
US20040087801A1 (en) 2004-05-06
WO1994004508A1 (en) 1994-03-03
AU5003793A (en) 1994-03-15
JPH08500118A (ja) 1996-01-09
EP0655059B1 (en) 1996-12-18
CA2136838A1 (en) 1994-03-03
DE69306794D1 (de) 1997-01-30

Similar Documents

Publication Publication Date Title
DK0948527T3 (da) Cylosporinderivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
NO834340L (no) Nye polypeptider
RU94045881A (ru) Производные пептидов, способ получения, фармацевтическая композиция, способ лечения
DE69131759T2 (de) An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one
ES2141148T3 (es) N-(dihidroxi-alquil)-etinil-alaninamidas terminadas en piperidinilo para el tratamiento de la hipertension.
ES2107192T3 (es) Compuestos de alquilamino etinil alanina amino diol morfolino/tiomorfolino-terminados utiles como inhibidores de renina.
ES2095749T3 (es) Compuestos de alquilamino etinil alanina amino diol imidazolil/bencimidazolil-terminados utiles para el tratamiento de la hipertension.
HUP9902465A1 (hu) Új amidínium-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0628042T3 (da) Serotoninerge ergolinderivater
GR3031861T3 (en) Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension.
ATE177736T1 (de) Pyridinyl/quinolinyl-endgruppen enthaltende alkylamino-ethynyl-alanin-amindiol derivate zur behandlung von bluthochdruck
ES2052535T3 (es) Sintesis de amino-alquil-amidas de peptidos o hidrazidas de peptidos mediante un metodo en fase solida.
ATE139444T1 (de) Carbocyklische nukleosidanaloge als immunsuppressoren
ES2104416T3 (es) Glicosilamidas de 2-aminoacilamino-2-desoxi-azucares.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655059

Country of ref document: ES